【摘要】 目的探讨血清细胞角蛋白19片段(即CYFRA21-1)检测在诊治源于上皮细胞的良性疾病中的意义。方法采用电化学发光免疫分析技术测定血清及胸腔积液中CYFRA21-1水平,通过生物素-亲和素结合而将KS19.1单克隆抗体-CYFRA21-1-三联二吡啶钌标记单抗BM19.21的夹心式复合物固定在亲和素包被的磁珠上。在三丙胺及电场的作用下发光以测定CYFRA21-1的值。结果患肺部疾病及并发症组CYFRA21-1水平明显高于单纯肺部疾病组(P<0.01),老年组CY-FRA21-1水平明显高于青壮年组(P<0.01)。结论对于患良性肺部疾病伴并发症的老年患者,如果检测出CYFRA21-1水平升高CEA、NSE正常者应进行对症治疗,2周后复检,以鉴别其良恶性。更多还原

【Abstract】 Objective To explore the clinical diagnostic value of CYFRA21-1 in benign lung disease deriving from epithelium cells.Methods CYFRA21-1 level in serum and hydrothorax was determined by electrochemiluminescence immunoassay. The complex sandwich (KS 19.1 monoclonal antibody-CYFRA21-1Ru(bpy)32+ labeled monoclonal antibody BMI 9.21) was fixed to the bead enclosed avidin by means of biotin-avidin combination,then the luminescence under the influence of perfluorotripropylamine and electric field luminous was tested for CYFRA21-1.Results The level of CYFRA21-1 in the group suffering from lung disease accompanied by complications was significantly higher than that of single lung disease group (P<0.01). CYFRA21-1 value in the elder group was significantly higher than that of the younger group (P<0.01).Conclusion The gerontal patients suffering from benign lung disease accompanied by complications should be given symptomatic treatment if their CYFRA21-1 level is elevated but CEA and NES was normal. Recheck the above indices two weeks later so as to identify the benign or malignancy of the disease.更多还原